• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research on August 25, 2021

    8/16/21 7:00:00 AM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGNE alert in real time by email

    BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast on Wednesday, August 25, 2021, at 9:30 a.m. ET to discuss the Company's early development pipeline and research.

    A live webcast of the conference call can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available after the event for 90 days.

    About BeiGene

    BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of approximately 7,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005187/en/

    Get the next $BGNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGNE

    DatePrice TargetRatingAnalyst
    12/3/2024$300.00Overweight
    Morgan Stanley
    9/18/2024$288.00Mkt Outperform
    JMP Securities
    2/6/2024$185.00Overweight
    JP Morgan
    9/12/2023$259.00Outperform
    Macquarie
    8/17/2023$287.00Buy
    Jefferies
    7/17/2023$275.00Buy
    Citigroup
    6/30/2023$335.00 → $196.00Outperform → Mkt Perform
    Bernstein
    1/12/2023$308.00Buy
    Daiwa Securities
    More analyst ratings

    $BGNE
    SEC Filings

    See more
    • BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      12/23/24 6:05:32 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeiGene Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - BeiGene, Ltd. (0001651308) (Filer)

      12/10/24 6:02:43 AM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by BeiGene Ltd.

      144 - BeiGene, Ltd. (0001651308) (Subject)

      12/9/24 9:48:25 PM ET
      $BGNE
      Biotechnology: Pharmaceutical Preparations
      Health Care